|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Anti-human hepatocellular carcinoma effects of tumor necrosis factor-related apoptosis-inducing ligand in vitro & in vivo.
|
11749866 |
2001 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Survivin ablation dramatically suppresses human and mouse HCCs by triggering senescence-associated TNFα and sensitizing HCC cells to TNFα-induced cell death.
|
27177758 |
2016 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
While the ORs for TNF-α-238 G/A, IL-1B-31 T/C, -511 C/T and IL-10-1082 G/A polymorphisms and HCC were 1.37 (0.95-2.00), 1.24 (0.99-1.55), 1.12 (0.66-1.88) and 0.91 (0.74-1.12), respectively.
|
21107607 |
2011 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adipose tissue is regarded as an endocrine organ that secretes proinflammatory cytokines such as tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6), which are related to the progression of hepatocellular carcinoma (HCC).
|
29976395 |
2018 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Inflammatory (TNF, LPS, IL-6) and profibrotic mediators (TGF-beta) do not regulate TUBA8 in HepG2 cells, primary HSC and the HSC cell line LX-2, when stimulated for 24 h. Agonists of the farnesoid X receptor and peroxisome proliferator activated receptor gamma, which are nuclear receptors involved in NASH and HCC pathophysiology, have no effect on TUBA8 in HepG2 and LX-2 cells.
|
28063004 |
2017 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The results showed that the AA and AG genotypes of TNFA -308G/A increased HCC susceptibility which was obvious among males, smokers, and alcohol drinkers, but not females, non-smokers, or non-drinkers (p=0.0003, 0.0003, 0.0014, 0.6127, 0.7442 and 0.3010, respectively).
|
26408704 |
2015 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To assess the contribution of tumor necrosis factor (TNF)β +252 polymorphisms to risk and prognosis of hepatocellular carcinoma (HCC), we enrolled 150 pairs of sex- and age-matched patients with HCC, patients with cirrhosis alone, and unrelated healthy controls.
|
25556449 |
2014 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Of note, the TPG-1 treatment significantly inhibited the tumorigenesis of human hepatoma HepG2 cells likely at least in part by increasing serum levels of TNFα and promoting leukocyte infiltration into tumors in nude mice.
|
30602571 |
2019 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study aimed to assess the association between tumor necrosis factor (TNF) alpha polymorphism and hepatic fibrosis, and risk for HCC.
|
18030367 |
2007 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
To observe the anti-liver cancer activity of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene and its bystander effects on hepatocellular carcinoma (HCC) cell line SMMC7721.
|
14991932 |
2004 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A significant decrease in the frequency of TNFα producing FcεRI<sup>+</sup> monocytes and mDCs in HCC and CCA patients when compared to the group of healthy individuals was observed, and a close association between FcεRI<sup>+</sup> monocytes and mDCs dysfunction was identified.
|
30828998 |
2019 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Association between EGF, TGF-β1 and TNF-α gene polymorphisms and hepatocellular carcinoma.
|
23464434 |
2012 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The levels of IL-2, IFN-γ and TNF-α in HCC tumor tissues were also analyzed by ELISA.
|
31710117 |
2019 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Further studies showed that intrahepatic proinflammatory cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α), were significantly elevated in HCC tissues.
|
23213087 |
2013 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We conducted a case-control study including 209 incident HCC cases and two control groups (275 hospital controls and 381 patients with chronic liver disease [CLD] without HCC) to investigate whether IL-1B and TNF-A gene polymorphisms influence HCC susceptibility with any interaction with alcohol and tobacco.
|
18603357 |
2008 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The distribution of this polymorphism and its impact on the serum level of TNF-α was compared between 90 HCV-infected patients [45 with HCV-induced cirrhosis and 45 with HCV-related hepatocellular carcinoma (HCC)] and 45 healthy Egyptian volunteers without any history of liver disease.
|
22200181 |
2012 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, the expression of eight candidate reference genes, B2M, ACTB, GAPDH, HMBS, HPRT1, TBP, UBC, and YWHAZ, was examined to identify optimal reference genes by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) analysis in two human hepatoma cell lines, BEL-7402 and SMMC-7721, treated with tumor necrosis factor-α (TNF-α) for different time periods.
|
23811755 |
2013 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Both tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and interleukin-12 (IL-12) have been emerged as promising pharmacological candidates in cancer therapy; however, the combined efficacy of TRAIL and IL-12 genes for treatment of human hepatocellular carcinoma (HCC) remains to be determined.
|
27154307 |
2016 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Significant higher risk of HCC was associated with: alleles IL-18 -607(*)A (P=0.0235; OR=1.48; 95%CI=1.06-2.08); TNF-α -238(*)A (P=0.0025; OR=2.12; 95%CI=1.32-3.40) and TNF-α -308(*)A (P=0.0351; OR=1.82; 95%CI=1.07-3.08); and genotypes IL-18-607AA (P=0.0048; OR=3.03; 95%CI=1.40-6.55); TNF-α -238GA (P=0.0011; OR=2.44; 95%CI=1.45-4.12); and TNF-α -308GA (P=0.0031; OR=2.51; 95%CI=1.39-4.51).
|
23632060 |
2013 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The present study showed that TNF-α -308 G > A polymorphism was associated with increased HCC risk in a Han Chinese population.
|
25420786 |
2014 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our meta-analyses suggest that TNF-<i>α</i> T-857C polymorphism may be associated with increased risk of gastric cancer and hepatocellular cancer development.
|
28115787 |
2016 |
|
Liver carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Increased risk of developing hepatocellular carcinoma associated with carriage of the TNF2 allele of the -308 tumor necrosis factor-alpha promoter gene.
|
15280623 |
2004 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The activation of NF-kappaB induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) renders hepatocellular carcinoma (HCC) resistant to TRAIL-mediated cell apoptosis.
|
16627981 |
2006 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Whole blood was obtained for analysis of T cell cytokines (IL-1β, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12p70, IL-13, IL-17A, IL-22, IFN-γ, and TNF-α) and Tregs from 142 HCC patients.
|
30824840 |
2019 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Therefore, we aimed to investigate the differential protein expression of HCC in response to TNFα stimulus.
|
28367089 |
2017 |